IC-SARI (STRIVE002A)
Immuno-Compromised Severe Acute Respiratory Infection (IC-SARI) study
An observational study into the causes of severe acute respiratory infections among people with immunocompromising conditions.
What is this study about?
IC-SARI is an observational, multicentre prospective cohort study conducted under the STRIVE 002 master protocol: An International Observational Study of Adults with Acute Infection.
This project will enrol adults with an immunocompromising (IC) condition admitted to the hospital with a severe acute respiratory infection (SARI).
Relatively little is known about the aetiology of severe acute respiratory infections among immunocompromised persons and whether the aetiology and/or clinical outcomes vary by different immunocompromising conditions or global regions. A global assessment is critical for understanding regional variation in immunocompromising conditions, pathogens causing severe disease in immunocompromised patients, and clinical outcomes.
There is a need for rigorous, prospective assessments of immunocompromised patients with severe respiratory infections to generate data that can be used to design new interventions and clinical trials, which will be necessary to curb the severe morbidity and mortality from this disease.
Network coordinating the study: Strategies & Treatments for Respiratory Infections and Viral Emergencies (STRIVE)
Type of study
Observational study
Contact details
Data Sharing
The Statistical and Data Management Centre (SDMC) at the University of Minnesota (UMN) is responsible for sharing the data collected as part of the trial.
Who is funding the study?
The study is funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health (USA).
When is it taking place?
The study opened in 2025 and will run for at least 3 years.
Where is it taking place?
The study is being conducted at sites in Africa, North and South America, Asia, Australia, and Europe. Sites under the remit of the MRC CTU at UCL (acting as the London International Coordinating Centre for STRIVE) are in Greece, Uganda, Zimbabwe and the UK
Who is included?
Adults aged 18 years or older with a moderate-to-severe immunocompromising condition hospitalised for SARI.